Hamoa...The point you make about the manner in which the judge dealt with Kurabayashi confirms my suspicion that she judged the case from her point of view, which did not treat both parties equally...and mitigated against Amarin.
Homoa, OT, but has anyone tried to sue a doctor for patent infringement? With more and more doctors being affiliated with a group...what about suing a hospital group with a large number of cardiologists as an example? If one of the doctors infringes from a large group, could you try hold the group responsible and sue them? You would only need one high profile case to send a message. Why is that not possible?
After diving deeper. It seems the examiner brought up 3 articles regarding apo B but didn’t cite this specific one Kurabayashi. It’s a totally worthless article scientifically but the fact that the Judge didn’t see it as worthless is unfortunate. It also sucks it wasn’t cited bc that could have helped us.
What’s your opinion on us removing our NDA for the marine label and us prescribing Vascepa based on reduce it label and off label for marine label. We don’t need the marine label anymore. Would that interfere with generics? Can we do something like that if we get desperate?